Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The other big challenge is, despite having ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. This is an exciting time to think about ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a ...

BERLIN — Lusvertikimab, a first-in-class interleukin 7 (IL-7) receptor antagonist, demonstrated clinical and endoscopic efficacy in patients with moderate to severe ulcerative colitis (UC) in the ...

Montai Therapeutics, a company harnessing AI to decode untapped, diverse chemistry to develop breakthrough medicines for chronic disease, will present preclinical data for the first time on its novel ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

However, they feel their findings provide a deeper understanding of IBDs and offer a way in which ulcerative colitis could be treated. “Our results indicate the relocation of bacteria from the mouth ...

ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing ...